Prevention of stroke for clinical purposes

被引：0

作者：

Grotemeyer, K-H. ^{[1
]}

Grotemeyer, K. C. ^{[1
]}

机构：

[1] Klinikum Saarbrucken, Neurol Klin, D-66119 Saarbrucken, Germany

来源：

NERVENHEILKUNDE | 2009年 / 28卷 / 11期

关键词：

Stroke; secondary prevention; aggregation inhibitors; anti-coagulation; costs; ACETYLSALICYLIC-ACID; SECONDARY PREVENTION; ATRIAL-FIBRILLATION; DOUBLE-BLIND; ASPIRIN; CLOPIDOGREL; TRIAL; RISK; DIPYRIDAMOLE; ATORVASTATIN;

D O I：

10.1055/s-0038-1627161

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The physician knows the guidelines from the German Neurology Society (DGN) for the prevention of a second stroke. However, for the treatment of a patient pragmatism is necessary and the costs for the system have to be regarded. Furthermore, clinical studies can leave unanswered questions. For the choice of the aggregation inhibitor the individual situation of the patient should be regarded. Blood pressure has to be observed and regulated. Lipid-lowering agents are effective for elderly patients as prevention, but not as first choice treatment. For every medical treatment, practical and clinical usefulness should be regarded.

引用

页码：789 / +

页数：6

共 50 条

[41] A Clinical Update on Antiplatelet Therapy in Secondary Prevention of Ischemic Stroke [J].

Marsden, Katelyn ;

Mak, Hannah Y. ;

Crooks, C. Patrick ;

Pankaj, Preethy ;

Thuhien Nguyen ;

Tirschwell, David .

CURRENT CARDIOLOGY REPORTS, 2021, 23 (10)

[42] Secondary stroke prevention in atrial fibrillation: a challenge in the clinical practice [J].

Christian Tanislav ;

Sonja Milde ;

Sabine Schwartzkopff ;

Nicole Sieweke ;

Heidrun Helga Krämer ;

Martin Juenemann ;

Björn Misselwitz ;

Manfred Kaps .

BMC Neurology, 14

[43] The antithrombotic treatment in the secondary prevention of ischemic stroke: strategy and tactic issues [J].

Gudkova, V. V. ;

Stakhovskaya, L. V. ;

Shanina, T. V. ;

Meshkova, K. S. ;

Shekhovtsova, K. V. .

ZHURNAL NEVROLOGII I PSIKHIATRII IMENI S S KORSAKOVA, 2011, 111 (11) :87-94

[44] What's new in stroke? Phase III randomized clinical trials of 2012-2014 [J].

Hart, Robert G. ;

Ng, Kuan H. ;

Perera, Kanjana S. ;

Shoamanesh, Ashkan .

INTERNATIONAL JOURNAL OF STROKE, 2015, 10 (06) :790-795

[45] Current Status of Antiplatelet Agents to Prevent Stroke [J].

Field, Thalia S. ;

Benavente, Oscar R. .

CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2011, 11 (01) :6-14

[46] Patients Enrolled in Large Randomized Clinical Trials of Antiplatelet Treatment for Prevention After Transient Ischemic Attack or Ischemic Stroke Are Not Representative of Patients in Clinical Practice The Netherlands Stroke Survey [J].

Maasland, Lisette ;

van Oostenbrugge, Robert J. ;

Franke, Cees F. ;

Reimer, Wilma J. M. Scholte op ;

Koudstaal, Peter J. ;

Dippel, Diederik W. J. .

STROKE, 2009, 40 (08) :2662-2668

[47] Prevention of stroke: What is evidence based? [J].

Lueders, S. ;

Schrader, J. .

INTERNIST, 2009, 50 (12) :1337-1343

[48] Antivitamin K Drugs in Stroke Prevention [J].

Di Raimondo, Domenico ;

Tuttolomondo, Antonino ;

Butta, Carmelo ;

Lucifora, Benedetto ;

Licata, Giuseppe ;

Pinto, Antonio .

CURRENT VASCULAR PHARMACOLOGY, 2013, 11 (06) :817-823

[49] Stroke: Secondary prevention of ischemic events [J].

Morris, Jane G. ;

Carter, Emily L. ;

Martin, Stephen A. .

JOURNAL OF FAMILY PRACTICE, 2017, 66 (07) :420-427

[50] Recurrent Ischemic Stroke: Strategies for Prevention [J].

Oza, Rupal ;

Rundell, Kristen ;

Garcellano, Miriam .

AMERICAN FAMILY PHYSICIAN, 2017, 96 (07) :436-440

← 1 2 3 4 5 →